Invention Grant
US08703419B2 Method for diagnosis/prognosis of cancers using an epigenetic marker consisting of a specific single CpG site in TTP promoter and treatment of cancers by regulating its epigenetic status
有权
使用由TTP启动子中的特定单个CpG位点组成的表观遗传标记和通过调节其表观遗传学状态来治疗癌症的癌症的诊断/预后的方法
- Patent Title: Method for diagnosis/prognosis of cancers using an epigenetic marker consisting of a specific single CpG site in TTP promoter and treatment of cancers by regulating its epigenetic status
- Patent Title (中): 使用由TTP启动子中的特定单个CpG位点组成的表观遗传标记和通过调节其表观遗传学状态来治疗癌症的癌症的诊断/预后的方法
-
Application No.: US13514913Application Date: 2010-09-08
-
Publication No.: US08703419B2Publication Date: 2014-04-22
- Inventor: Young Il Yeom , Bo Hwa Sohn , In Young Park , Jung Ju Lee , Yejin Jang , Suk-jin Yang , Kyung Chan Park , Hyang-sook Yoo , Jong Young Choi
- Applicant: Young Il Yeom , Bo Hwa Sohn , In Young Park , Jung Ju Lee , Yejin Jang , Suk-jin Yang , Kyung Chan Park , Hyang-sook Yoo , Jong Young Choi
- Applicant Address: KR Daejeon
- Assignee: Korea Research Institute of Bioscience and Biotechnology
- Current Assignee: Korea Research Institute of Bioscience and Biotechnology
- Current Assignee Address: KR Daejeon
- Agency: Klarquist Sparkman, LLP
- Priority: KR10-2009-0123321 20091211
- International Application: PCT/KR2010/006113 WO 20100908
- International Announcement: WO2011/071232 WO 20110616
- Main IPC: C12N15/10
- IPC: C12N15/10
Abstract:
The present invention relates to a method for the diagnosis and prognosis of cancers using an epigenetic marker consisting of a specific single CpG site in TTP (Tristetraprolin) promoter and treatment of cancers by regulating its epigenetic status. Particularly, the present invention relates to a method for the diagnosis and prognosis of liver cancer by measuring specific methylation of C, the 32nd residue of the nucleic acid sequence represented by SEQ. ID. NO. 41, and a method for treatment of cancer by regulating the same. The present invention can be effectively used for the diagnosis and/or treatment of liver cancer characterized by TTP down-regulation and methylation of C, the 32nd residue of the nucleic acid sequence represented by SEQ. ID. NO. 41. The present invention can be further applied for the diagnosis and treatment of other cancers or inflammatory diseases that are characterized by TTP down-regulation and methylation of C, the 32nd residue of the nucleic acid sequence represented by SEQ. ID. NO. 41.
Public/Granted literature
Information query
IPC分类:
